🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Henan Cancer Hospital72 The First Affiliated Hospital of Zhengzhou University39 Merck Sharp & Dohme LLC27 AbbVie21 Novartis Pharmaceuticals20
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Zhengzhou

921 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
NCT07175493Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome
Keymed Biosciences Co.Ltd
Phase 1/2
158
Zhengzhou, Changzhi, Tianjin
2025-11-18
Recruiting
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
Beijing Gene Key Life Technology Co., Ltd
Phase 2
48
Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou
2025-11-14
Recruiting
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
NCT07239245Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing, Zhengzhou, Shenyang, Taiyuan
2025-11-12
Recruiting
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
NCT07207070Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
312
Beijing, Zhengzhou
2025-11-12
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals
Phase 3
1,275
Guangzhou, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang, Yinchuan
2025-11-11
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07181681Solid Tumors, Advanced Solid Tumor
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
NCT06902740Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
300
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2025-11-07
Active, closed
A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection
NCT07245953Chronic Hepatitis B
Suzhou HepaThera Biotech Co., Ltd.
Phase 2
60
Beijing, Fuzhou, Guangzhou, Qingyuan, Nanning, Zhengzhou, Nanjing, Zhenjiang
2025-11-05
By invitation
AI-Assisted Pathologist Performance Improvement: A Multicenter, Prospective, Randomized Controlled Trial
NCT07291362Pathology Foundation Model
Nanfang Hospital, Southern Medical University
Not applicable
1,000
Guangzhou, Zhengzhou
2025-11-01
Not yet open
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
NCT07187960Follicular Lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
228
Beijing, Chongqing, Lanzhou, Guangzhou, Guiyang, Haikou, Harbin, Zhengzhou
2025-11
Recruiting
To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
NCT07208591Acute Respiratory Distress Syndrome (ARDS)
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
406
Beijing, Xiamen, Guangzhou, Zunyi, Luoyang, Zhengzhou, Wuhan, Xiangtan
2025-10-31
Recruiting
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT07205822Breast Cancer
AstraZeneca
Phase 3
100
Beijing, Changsha, Guangzhou, Linyi, Shandong, Wuhan, Zhengzhou
2025-10-30
Recruiting
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
NCT07569653Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
WeiShi
Phase 4
120
Beijing, Shijiazhuang, Zhengzhou, Jingzhou, Wuhan, Hohhot, Nanchang, Wenzhou
2025-10-30
Recruiting
A Phase Ⅱ/Ⅲ Study of HRS-2129 for Postsurgical Pain Management in Abdominal Surgery
NCT07185594Postoperative Analgesia
Shandong Suncadia Medicine Co., Ltd.
Phase 2/3
360
Zhengzhou, Hangzhou
2025-10-24
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb
Phase 2/3
470
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Luoyang, Zhengzhou
2025-10-23
Recruiting
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
NCT07272434Respiratory Syncytial Virus (RSV)
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Xi'an, Jinan, Chengdu
2025-10-22
Recruiting
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
NCT07259590Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
126
Beijing, Guangzhou, Zhengzhou, Wuhan
2025-10-21
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
NCT07111546Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
140
Hefei, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Xiangyang, Changsha
2025-10-20
Recruiting
Desflurane vs. Propofol for Cardiac Anesthesia
NCT07116733Cardiac Surgery, Coronary Artery Bypass Grafting
Xijing Hospital
Phase 3
3,560
Fuzhou, Cangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjin, Xi'an, Chengdu
2025-10-20
Not yet open
Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP
NCT07200336Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Eye & ENT Hospital of Fudan University
Phase 4
360
Chongqing, Fuzhou, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2025-10-08
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
Not yet open
A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
NCT07156617Hepatocellular Carcinoma (HCC)
Xuhua Duan
Observational
2,000
Haikou, Xingtai, Dengzhou, Jiaozuo, Kaifeng, Luoyang, Shangqiu, Zhengzhou
2025-10-01
Not yet open
A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes
NCT07122102Type 2 Diabetes
Haisco Pharmaceutical Group Co., Ltd.
Not applicable
200
Zhengzhou
2025-10-01
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
Bristol-Myers Squibb
Phase 2/3
470
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong
2025-09-30
Not yet open
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
NCT07125950Advanced Breast Cancer
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2025-09-30
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
Fuzhou, Xiamen, Guangzhou, Huizhou, Zhengzhou, Wuhan, Changchun, Binzhou
2025-09-29
Recruiting
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
NCT07205315B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL), Autoimmune Hemolytic Anemia (AIHA)
Grit Biotechnology
Phase EARLY_PHASE1
28
Zhengzhou, Tianjin
2025-09-26
Recruiting
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou
2025-09-25
Recruiting
A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia
NCT07243379Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia, Multicenter Observational Study
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 4
495
Zhengzhou
2025-09-25
Recruiting
A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors
NCT06953453Cancer
Lee's Pharmaceutical Limited
Phase 1
100
Zhengzhou, Shanghai
2025-09-23
Recruiting
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
NCT07141706Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1
253
Guangzhou, Harbin, Zhengzhou, Jinan
2025-09-23
Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals
Phase 2
66
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou
2025-09-22
Recruiting
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
NCT07357623Pulmonary Neuroendocrine Tumor
Shanghai Chest Hospital
Phase 2
96
Hefei, Beijing, Zhengzhou, Shanghai
2025-09-22
Recruiting
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
NCT07164170Non-Small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd
Phase 2
86
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2025-09-22
Recruiting
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
NCT07215650Generalized Myasthenia Gravis
Candid Therapeutics
Phase 1
44
Fuzhou, Guangzhou, Guiyang, Zhengzhou, Changchun, Shanghai, Taiyuan, Chengdu
2025-09-16
Not yet open
Disease-syndrome Characteristics of IPF
NCT07178392Idiopathic Pulmonary Fibrosis (IPF)
Henan University of Traditional Chinese Medicine
Observational
2,864
Zhengzhou
2025-09-15
Recruiting
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT07174908Non-Small Cell Lung Cancer
InxMed (Shanghai) Co., Ltd.
Phase 3
400
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang
2025-09-10
Recruiting
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
NCT06824103Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
Novartis Pharmaceuticals
Phase 4
50
Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-09-09
Not yet open
Reinforcement Learned Automated Anesthesia Systems During Painless Abortion
NCT07132151Painless Abortion, Artificial Intelligence (AI), Ciprofol
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Not applicable
167
Fuzhou, Jinjiang, Quanzhou, Shenzhen, Zhengzhou, Chengdu, Chongqing
2025-09-08
Recruiting
Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer
NCT07559097Leptomeningeal Metastasis From Lung Cancer
Henan Cancer Hospital
Phase 1/2
14
Zhengzhou
2025-09-08
Recruiting
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
NCT06967103Breast Cancer, HR+/HER2- Breast Cancer
Henan Cancer Hospital
Phase 2
238
Zhengzhou
2025-09-08
Recruiting
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
NCT07102901Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
351
Harbin, Zhengzhou
2025-09-05
Not yet open
Idiopathic Pulmonary Fibrosis Cohort of TCM
NCT07162870Idiopathic Pulmonary Fibrosis (IPF)
Henan University of Traditional Chinese Medicine
Observational
1,000
Zhengzhou
2025-09-05
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663Systemic Lupus Erythematosus (SLE)
Candid Therapeutics
Phase 1
47
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-09-04
Recruiting
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
NCT07137910Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Jilin City, Chongqing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou
2025-09-04
Not yet open
Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules
NCT07135297Lung Cancer (Diagnosis)
Shanghai Chest Hospital
Not applicable
465
Beijing, Zhengzhou, Nanjing, Ningbo, Shanghai
2025-09-01
Not yet open
CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation
NCT07117305CD7+ Lymphoma, T Cell Lymphoma
Zhengzhou University
Phase 1/2
38
Zhengzhou
2025-09-01
Recruiting
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
NCT07170345Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI)
Chinese Academy of Sciences
Observational
400
Fuzhou, Guangzhou, Zhuhai, Nanning, Guiyang, Zhengzhou, Shenyang, Chengdu
2025-09-01
Not yet open
A Study on Cardiopulmonary Exercise Tolerance Standards for Healthy Chinese Population
NCT07108296Oxygen Consumption, Cardiorespiratory Fitness
Affiliated Hospital of Changchun University of Chinese Medicine
Observational
4,620
Beijing, Quanzhou, Guangzhou, Nanning, Daqing, Harbin, Puyang, Zhengzhou
2025-09-01
Recruiting
Plasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation
NCT07113769ExtraCorporeal Membrane Oxygenation (ECMO), Cardiac Arrest
Central China Fuwai Hospital of Zhengzhou University
Observational
130
Zhengzhou
2025-09-01
Not yet open
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
NCT07136974Breast Cancer, HER2 + Breast Cancer
Henan Cancer Hospital
Phase 2
280
Zhengzhou
2025-09-01
Recruiting
Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens
NCT07694648Respiratory Tract Infections (RTI), Respiratory Syndrome, Acute, Severe, Acute Respiratory Infections (ARIs)
Huashan Hospital
Observational
2,398
Beijing, Guangzhou, Zhuhai, Shijiazhuang, Harbin, Jiamusi, Shangqiu, Zhengzhou
2025-09-01
Recruiting
A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B
NCT07307586Chronic Hepatitis B, Azvudine
Zhigang Ren
Phase 3
120
Zhengzhou
2025-09-01
Not yet open
Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
NCT07131150Idiopathic Pulmonary Fibrosis (IPF)
Ruijin Hospital
Phase 2
66
Beijing, Guangzhou, Shenzhen, Hebei, Zhengzhou, Wuhan, Changsha, Nanjing
2025-08-31
Recruiting
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
NCT07100600HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy
Henan Cancer Hospital
Phase 2
224
Zhengzhou
2025-08-30
Recruiting
A Study of SKB518 in Patients With Lung Cancer
NCT07019675Lung Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
192
Shenzhen, Nanning, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanchang, Jinan
2025-08-29
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Beijing, Harbin, Zhengzhou
2025-08-28
Recruiting
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06841679Gastric or Gastroesophageal Junction Adenocarcinoma
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2/3
778
Anyang, Guangzhou, Jinan, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
2025-08-28
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
BeOne Medicines
Phase 3
351
Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang
2025-08-27
Recruiting
LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft
NCT07773051Arteriovenous Graft
Longhua Hospital
Not applicable
326
Beijing, Chongqing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nanchang
2025-08-25
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Phrontline Biopharma
Phase 1
200
Zhengzhou, Wuhan, Hangzhou, Shanghai
2025-08-25
Recruiting
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
NCT07082686Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
75
Hefei, Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Zhengzhou
2025-08-21
Recruiting
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706Non-small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc.
Phase 3
180
Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Nantong, Nanchang
2025-08-21
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
Recruiting
Research on Identifying Critical Surgical Anatomy in Cholecystectomy Videos Based on Deep Learning
NCT07158372Cholecystectomy, Surgical Video Identification
Chinese Academy of Sciences
Observational
200
Zhengzhou, Beijing, Shanghai
2025-08-15
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
150
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-08-14
Recruiting
Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease
NCT07031531Premature Coronary Heart Disease
China National Center for Cardiovascular Diseases
Not applicable
4,900
Hefei, Beijing, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Nanjing, Yangzhou
2025-08-08
Recruiting
Interventional Left Ventricular Assist System for PCI in CHIP Patients
NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
286
Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang
2025-08-06
Recruiting
Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation
NCT06871228Atrial Fibrillation (AF)
Beijing Anzhen Hospital
Not applicable
4,100
Hefei, Beijing, Guangzhou, Shijiazhuang, Harbin, Luohe, Zhengzhou, Wuhan
2025-08-05
Recruiting
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
NCT06615596Atrial Fibrillation (AF)
China National Center for Cardiovascular Diseases
Phase EARLY_PHASE1
3,160
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Shanghai, Taiyuan, Chengdu
2025-08-05
Not yet open
29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
NCT07100236Primary Hepatocellular Carcinoma
Junjie Xu
Observational
350
Hefei, Chaoyang, Fuzhou, Guangzhou, Zhengzhou, Shanghai, Hangzhou, Wenzhou
2025-08-01
Recruiting
A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies
NCT07113925Advanced Hematologic Malignancies
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
114
Zhengzhou, Nanchang, Shanghai
2025-08-01
Not yet open
Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF
NCT06914713Idiopathic Pulmonary Fibrosis(IPF)
Henan University of Traditional Chinese Medicine
Not applicable
384
Zhengzhou
2025-08-01
Recruiting
Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD
NCT07523880Thrombosis, Bleeding, Coronary Artery Disease (CAD)
Xueyan Zhao
Observational
12,154
Zhengzhou, Shenyang, Beijing
2025-08-01
Recruiting
CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD
NCT06820970Coronary Artery Disease
Henan Institute of Cardiovascular Epidemiology
Not applicable
2,000
Zhengzhou
2025-08-01
Not yet open
Laparoscopic Adventitial Renal Denervation (RDN) for Refractory Hypertension
NCT07108829Refractory Hypertension or Drug-intolerant Hypertension
Henan Institute of Cardiovascular Epidemiology
Not applicable
10
Zhengzhou
2025-08
Recruiting
A Clinical Study of GO306 in Patients With Advanced Solid Tumors
NCT07128914Solid Tumor Malignancies
GeneSail Biotech (Shanghai) Co., Ltd.
Phase 1
32
Hefei, Fuzhou, Shenzhen, Zhengzhou, Changsha, Shanghai
2025-07-31
Not yet open
Clinical Trial of Freeze-dried Human Rabies Vaccine (Human Diploid Cells)
NCT07028801Rabies
Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Phase 3
3,000
Zhengzhou
2025-07-31
Recruiting
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
NCT07124936Diffuse Large B Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
97
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2025-07-30
Recruiting
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
NCT06780111Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
298
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Nanchang
2025-07-30
Active, closed
A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis
NCT06909136Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly
Suzhou Junjing BioSciences Co., Ltd.
Phase 1/2
33
Zhengzhou
2025-07-28
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519Ulcerative Colitis
AbbVie
Phase 3
120
Guangzhou, Zhengzhou, Changsha, Changchun, Shanghai, Hangzhou
2025-07-28
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
NCT06918834Myelodysplastic Syndromes
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
236
Beijin, Zhengzhou, Jinan, Chengdu, Shijia Zhuang
2025-07-24
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
PharmaEssentia
Phase 3
160
Beijing, Chongqing, Guangdong, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2025-07-18
Recruiting
A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
NCT07043751Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
216
Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha
2025-07-15
Recruiting
Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta
NCT07025954Placenta Previa, Placenta Accreta Spectrum, Antepartum Bleeding, Emergency Cesarean Section
The Third Affiliated Hospital of Guangzhou Medical University
Not applicable
600
Guangzhou, Zhengzhou, Chengdu, Beijing, Chongqing
2025-07-12
Recruiting
A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)
NCT07202728Hydatidiform Mole
Obstetrics & Gynecology Hospital of Fudan University
Observational
1,489
Lanzhou, Shenzhen, Haikou, Shijiazhuang, Zhengzhou, Dalian, Shenyang, Jinan
2025-07-09
Recruiting
MITRIS China Post Market Clinical Follow-up (PMCF) Study
NCT07059793Mitral Valve Replacement
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Xi'an, Jinan
2025-07-08
Recruiting
Post-Market Clinical Study to Evaluate the Safety and Effectiveness of REFLEX ULTRA 45 for Coblation Inferior Turbinate Reduction in China
NCT07025304Nasal Obstruction Due to Inferior Turbinate Hypertrophy
Smith & Nephew, Inc.
Not applicable
105
Guangzhou, Zhengzhou, Nanjing, Changchun, Hangzhou
2025-07-02
Not yet open
DCB for CAD With Type 2 Diabetes
NCT07009938Coronary Artery Disease, Diabete Type 2
Shanghai 10th People's Hospital
Not applicable
1,000
Kaifeng, Luoyang, Zhengzhou, Shanghai, Yibin, Ningbo
2025-07-01
Recruiting
A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer
NCT07770113GC/GEJC
The First Affiliated Hospital of Zhengzhou University
Phase 2
50
Zhengzhou
2025-06-30
Recruiting
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
NCT07071090Solid Tumor Malignancies
Heronova Pharmaceuticals
Phase 1
32
Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha, Jinan, Hangzhou
2025-06-30
Recruiting
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001
NCT07264569Meningeal Metastasis
Henan Cancer Hospital
Phase 1/2
42
Zhengzhou
2025-06-25
Recruiting
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
NCT07057427Breast Cancer
Henan Cancer Hospital
Phase 3
812
Zhengzhou
2025-06-24
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
642
Hefei, Beijing, Lanzhou, Shantou, Harbin, Kaifeng, Puyang, Zhengzhou
2025-06-23
Recruiting
A Study in Children With Achondroplasia
NCT07301463Achondroplasia
Abbisko Therapeutics Co, Ltd
Observational
260
Beijing, Guangzhou, Zhengzhou, Wuhan, Shanghai, Chengdu, Hangzhou
2025-06-20
Recruiting
The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
NCT06995118Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Du Zhenggui
Not applicable
337
Fuzhou, Guangzhou, Anyang, Zhengzhou, Changsha, Hohhot, Suzhou, Nanchang
2025-06-17
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
AbbVie
Phase 3
573
Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2025-06-17
Active, closed
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
NCT06941792Coronary Heart Disease
Novartis Pharmaceuticals
Phase 4
1,590
Anqing, Beijing, Chongqing, Longyan, Jiamusi, Zhengzhou, Baotou, Shenyang
2025-06-17
Rows per page Showing 201–300 of 921
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 921 of those studies with a site in Zhengzhou.

How many clinical trials are recruiting in Zhengzhou?

553 of the 921 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 163 have not yet opened recruitment, 191 are active but closed to new participants, and 14 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.